Hims & Hers
Hims & Hers is a direct-to-consumer telehealth platform offering online consultations and prescription delivery for hair loss, erectile dysfunction, skincare, mental health, and weight loss treatments. The platform connects patients with licensed healthcare providers through asynchronous messaging and video visits, primarily targeting younger adults seeking convenient, stigma-free access to common health conditions.
Score generated by AI agents based on publicly cited evidence and reviewed by the project maintainer. Not independently validated. Last assessed 2026-10-01. Score revised 2026-10-01: 52 → 49.
Score History
Timeline events are AI-curated from public reporting. Score trajectory is derived from documented events.
Hims launched in November 2017 selling hair-loss and ED treatments by subscription, added the Hers brand in 2018 and mental-health services in 2020. Pricing was simple and the service was a genuine convenience for users. Per the FTC's later complaint, most customers could cancel only by contacting customer service before 2023, the main early sign of exit friction.
The SPAC listing brought public-market growth pressure and a dual-class structure giving Dudum about 90% of voting power. Marketing ran near half of revenue, multi-month prepaid plans covered 73% of members by the end of 2022, and BBB complaints about billing and cancellation passed 200 by May 2023. A December 2022 STAT/Markup investigation found Hims' trackers telling ad platforms about prescription purchases, and the FTC opened a non-public probe in October 2023.
Hims began selling compounded semaglutide at $199 a month under the FDA drug-shortage exemption, and it quickly became its fastest-growing line. It bought the MedisourceRx compounding pharmacy, authorized a $100 million buyback and paid Dudum $24.6 million for 2024. A law firm investigated charges after cancellation, and the February 2025 Super Bowl ad drew Senate criticism for omitting safety information.
The FDA declared the semaglutide shortage over, removing the basis for mass compounding, but Hims kept selling 'personalized' compounded doses. Novo Nordisk ended a two-month partnership in June 2025 over alleged illegal mass compounding; the FDA issued warning letters for false or misleading claims and to the MedisourceRx pharmacy, and the FTC probe became public. Dudum sold over $46 million of stock in a year with a 4% layoff. A $49 compounded pill in February 2026 drew an HHS referral to the DOJ, an SEC probe and a Novo patent suit.
Novo dropped its suit as Hims agreed to sell Wegovy and Ozempic and stop advertising compounded GLP-1s, moving weight-loss customers to branded drugs billed alongside a $149 monthly membership. Hims closed the Eucalyptus deal abroad and ran net losses on lower margins. In July 2026 the FTC, Utah and California sued over deceptive enrollment, hidden cancellation and health-data sharing; Hims accrued $60 million and is contesting it, while the SEC and DOJ matters remain open.
Alternatives
The closest direct competitor for DTC telehealth covering ED, hair loss, weight management, and skincare, with the same convenient online model. Switching is easy: cancel Hims, sign up with Ro, and restart your care consultation. Ro has its own subscription model, so read the cancellation terms carefully before committing.
Broader telehealth platform that covers primary care, mental health, dermatology, and chronic conditions. Works with many insurance plans, whereas Hims & Hers is cash-pay. Less specialized for conditions like ED or hair loss, but a more conventional service model without the subscription billing and cancellation practices the FTC sued Hims over in 2026.
Dimensional Breakdown
Summaries below were written by AI agents based on the cited evidence. They are editorial interpretations, not independent research findings.
Dimension History
Timeline (49 events)
Hims Launches DTC Men's Telehealth Platform
Hims launched in November 2017 as a direct-to-consumer telehealth startup focused on men's health, initially offering treatments for hair loss and erectile dysfunction under a destigmatization-focused brand aimed at younger men. Co-founder and CEO Andrew Dudum led the San Francisco company, which was backed by Founders Fund, Redpoint Ventures, Forerunner Ventures, SV Angel and 8VC.
Hers Brand Expands Platform to Women's Health
Exactly one year after launching Hims, the company introduced the Hers brand for women's health, offering sexual wellness (including a prescription birth control pill and Addyi), skin care, and hair loss treatments. Apart from birth control and Addyi, products ranged from $15 to $75 per month.
COVID-Driven Mental Health Services Launch
Hims & Hers expanded into mental health during the COVID-19 pandemic, starting with free anonymous group support sessions led by licensed mental health professionals and guided meditation, and announced plans for individual online therapy and psychiatric evaluations with medication prescribing. A psychiatry service for depression and anxiety medication followed in July 2020.
Hims & Hers Goes Public via SPAC Merger
Hims & Hers completed its merger with Oaktree Acquisition Corp., valuing the company at $1.6 billion. The deal generated $279.5 million in proceeds, with $204.5 million from the SPAC trust and $75 million from private investors including Franklin Templeton. Management rolled 90-100% of their equity into the combined entity, and shares began trading on NYSE under HIMS.
Apostrophe Acquisition for $190 Million
Hims & Hers agreed to acquire teledermatology platform Apostrophe, gaining a vertically integrated mail-order pharmacy licensed in 29 states and a board-certified dermatology network; the deal was positioned as accelerating scale in dermatology. Terms were not disclosed at announcement (Fierce later put the price at $190 million; SEC filings show about $150 million upfront plus up to $50 million in earn-outs). Hims shut Apostrophe down in March 2025 to fold it into its own dermatology offering.
Investigation Reveals Health Data Shared with Big Tech
A joint STAT/The Markup investigation of 50 direct-to-consumer telehealth websites found that trackers on 25 sites, including those run by Hims & Hers, told at least one big tech platform (Meta, Google, TikTok, Bing, Snap, Twitter, LinkedIn or Pinterest) when a user added an item such as a prescription medication to their cart or checked out with a treatment subscription. On 13 of the sites, trackers also collected answers to medical intake questions.
Glassdoor Reviews Document Toxic Workplace Culture
Glassdoor reviews from 2023 onward described workplace culture problems at Hims & Hers. A January 2023 review titled 'Lack of Structure, Diversity, and Toxic Company Culture' said roles were 'created out of thin air' with undefined expectations; other reviews said HR offered 'empty promises and lip service while the harassment continued unchecked' and that advancement depended on being 'a favorite with senior leadership' rather than merit.
Marketing Spend Doubles to $272 Million in 2022
Hims & Hers' marketing expense reached $272.6 million in 2022, a 100.6% year-over-year increase, roughly 52% of the company's $526.9 million revenue. The spending helped lift subscribers past 1 million, an 88% year-over-year increase. The aggressive spend-to-grow ratio signaled prioritization of subscriber acquisition over profitability.
Subscription Lock-in Deepens with Multi-Month Plans
By the end of 2022, 73% of Hims & Hers members were on multi-month subscriptions, according to the company's Q4 2022 earnings call, with retention rates around 85%. Multi-month plans lower the per-month price but bill in advance, adding financial commitment to the ongoing prescription relationship.
BBB Complaints Pass 200 as Subscription Friction Grows
By May 2023, the Better Business Bureau profile for Hims & Hers listed 203 complaints in the prior three years, 142 of them closed in the previous 12 months, with consumers citing billing, cancellation and refund problems as the company prioritized rapid subscriber growth. The count kept climbing: by September 2026 the profile listed about 4,500 complaints over three years.
FTC Issues Civil Investigative Demand Over Privacy, Advertising and Cancellation Practices
In October 2023 the FTC issued Hims & Hers a Civil Investigative Demand requesting information about its privacy, advertising and subscription cancellation practices as part of a non-public investigation. The company disclosed that it was cooperating and later said it had substantially completed its responses.
Marketing Spend Hits 51% of Revenue as Growth Prioritized
Hims & Hers spent $116.1 million on marketing in Q3 2023, about 51% of quarterly revenue of $226.7 million. Full-year 2023 marketing of $446.4 million was again roughly half of revenue, which grew 65% to $872 million, a spend ratio that raised questions about sustainable unit economics.
Class Action Investigation into Auto-Renewal Practices
Law firm Ahdoot & Wolfson opened a class action and mass arbitration investigation into Hims & Hers, citing reports and public complaints that the company kept charging customers' cards after they cancelled or removed payment information, and that its services were very difficult to cancel.
Compounded Semaglutide Injections Launched at $199/Month
Hims & Hers began offering compounded injectable semaglutide for weight loss at $199/month, exploiting an FDA shortage designation that permitted compounding pharmacies to produce copies of Novo Nordisk's Wegovy. The offering quickly became the company's fastest-growing product line, contributing over $200 million to 2024 revenue.
Hims Launches $100 Million Stock Buyback Program
Hims & Hers' board authorized a $100 million share repurchase program on July 24, 2024, following a $50 million program approved in October 2023. The $100 million program was fully used by early November 2025, during a year in which CEO Dudum sold more than $46 million of his own shares.
MedisourceRx Compounding Pharmacy Acquired for $31 Million
Hims & Hers closed its acquisition of MedisourceRx, a California 503B outsourcing facility, in September 2024 for about $31.0 million ($15.5 million in cash and $15.5 million in Class A stock), bringing compounding of medications in-house. An FDA inspection in May–June 2025 later noted vermin in the facility and an unreported serious adverse event.
Amazon Telehealth Entry Crashes Hims Stock 24%
Amazon launched fixed-price telehealth treatment for conditions including hair loss and erectile dysfunction for Prime members through Amazon One Medical's pay-per-visit service ($29 messaging visits, $49 video visits), with medications filled by Amazon Pharmacy. Hims & Hers stock closed down more than 24%, its worst day on record. Bank of America downgraded the stock to 'underperform,' estimating Amazon's medications for those conditions were about 29-42% cheaper.
$1 Million Donation to Trump Inauguration Fund
Hims & Hers donated $1 million to President-elect Trump's inaugural committee, the first digital health company to do so, according to Axios. The donation reportedly came with access to exclusive events with Trump and Vice President-elect Vance. It came amid uncertainty over how the incoming administration would treat compounded GLP-1 drugs, Hims' fastest-growing business.
Super Bowl Ad Draws Backlash for Misleading GLP-1 Claims
Hims & Hers aired a 60-second 'Sick of the System' Super Bowl ad promoting compounded semaglutide without disclosing side effects or safety information. Senators Durbin and Marshall warned it 'risks misleading patients.' The Partnership for Safe Medicines called it 'nothing short of reckless.' Novo Nordisk responded with full-page newspaper ads asking 'Do you really know what you're injecting?'
FDA Removes Semaglutide from Drug Shortage List
The FDA declared the semaglutide shortage resolved, ending the basis on which compounders could mass-produce copies after a 60-90 day grace period. Hims & Hers shares fell 26% that day. The company, whose GLP-1 offering generated more than $225 million in 2024 revenue, said compounded semaglutide would likely no longer be offered after the first quarter except where clinically necessary, and that it would notify patients to look for alternatives.
Apostrophe Teledermatology Platform Abruptly Shut Down
Hims & Hers shut down Apostrophe, the teledermatology brand it acquired in 2021 (for $190 million, per Fierce). Subscriptions were cancelled as of March 7 and customers kept account access for 30 days. The company said it was simplifying its dermatology products into one experience; patients could move to Hims & Hers' own dermatology offering or transfer prescriptions to a pharmacy of their choice.
Novo Nordisk Partnership to Sell Branded Wegovy
Hims & Hers announced a partnership with Novo Nordisk to sell branded Wegovy through NovoCare Pharmacy on its platform, bundled with a Hims & Hers membership starting at $599/month. The deal came weeks before the FDA's grace period for compounded semaglutide ended on May 22. Hims said it would keep offering its other weight loss products, and it continued selling 'personalized' compounded semaglutide, which Novo later cited when ending the deal.
68 Employees Laid Off Amid GLP-1 Regulatory Disruption
Hims & Hers cut 68 employees, about 4% of its workforce, across multiple teams. The cuts came days after the FDA's ban on mass-compounded Wegovy copies took effect, though the company said they were unrelated to the regulatory change. They came in a year in which CEO Dudum sold more than $46 million of his own shares.
Zava European Telehealth Acquisition Announced
Hims & Hers announced plans to acquire Zava, a European telehealth platform operating in the UK, Germany, France and Ireland, adding 1.3 million customers to its existing 2.4 million subscribers. The deal, which closed in July 2025, expanded the company geographically as its US compounded-drug business came under regulatory pressure.
Novo Nordisk Terminates Partnership, Stock Crashes 34.6%
Novo Nordisk ended its collaboration with Hims & Hers about eight weeks after it began, saying Hims had failed to adhere to the law prohibiting mass sales of compounded drugs 'under the false guise of personalization' and was disseminating deceptive marketing that put patient safety at risk. Hims shares fell 34.6% that day, from $64.22 to $41.98.
Securities Class Action Lawsuit Filed Against Hims
Two securities class actions were filed in the Northern District of California against Hims, CEO Andrew Dudum and CFO Yemi Okupe, later consolidated as In re Hims & Hers Health, Inc. Securities Litigation. The amended complaint covers purchasers between April 29 and June 22, 2025 and alleges the company misrepresented its business and its relationship with Novo Nordisk. Shareholder derivative suits followed in July and August 2025.
CEO Dudum Sells $33 Million in Largest Insider Trade
CEO Andrew Dudum sold 660,000 shares worth about $33 million through a family trust, the largest insider transaction since Hims went public. The sale was made on the open market rather than through his scheduled trading plan. With earlier sales of about $2.5 million in July and a further $11 million in October under a plan adopted in August 2024, his 2025 sales exceeded $46 million while the company faced an FTC investigation and securities litigation.
FTC Probe into Cancellation Practices Revealed
Bloomberg reported that the FTC had been investigating Hims & Hers for more than a year, including whether it made subscriptions too hard to cancel, with the probe covering cancellation flows, disclosure language and whether marketing crossed legal lines. Hims stock fell about 5-7% after hours, adding to investor concerns from the pending securities class action.
FDA Issues Warning Letters for Misleading Drug Marketing
The FDA issued formal warning letters to both Hims and Hers entities for misleading marketing of compounded semaglutide products. The FDA found claims were 'false or misleading' under the FDCA, including telling customers that compounded products contained 'the same active ingredient' as Ozempic and Wegovy. The products were declared misbranded drugs introduced into interstate commerce in violation of federal law.
$250 Million Stock Buyback Program Announced
Hims & Hers announced a new $250 million share repurchase program over three years, following the completion of its initial $100 million buyback. CEO Dudum stated the market 'may not fully reflect what we believe is its intrinsic value.' The buyback came while Dudum was simultaneously conducting tens of millions in personal stock sales and the company faced multiple regulatory investigations.
Hims Enters Canada by Acquiring Livewell
Hims & Hers entered Canada by acquiring Montreal-based Livewell, aiming to sell generic semaglutide once it becomes available there, since Canada is the first major market where the drug loses legal protection. The Globe and Mail reported that Hims estimates in investor presentations it holds about 47% of the US virtual-care market.
FDA Warning Letter to Hims-Owned MedisourceRx After Inspection Found Vermin, Unreported Adverse Event
After a May–June 2025 inspection of MedisourceRx, the Hims-owned compounding facility, in which investigators noted a live spider in the area storing active ingredients (including semaglutide) and a dead cricket in the incubator room, the FDA issued a warning letter on December 12, 2025. The letter cited the facility's failure to report a serious adverse event; STAT reported the patient was hospitalized for three nights after taking compounded semaglutide. The letter became public in February 2026.
Compounded Semaglutide Pill Announced at $49/Month
Hims & Hers announced a compounded semaglutide pill at $49 for the first month and $99 a month thereafter, positioning it as a cheaper alternative to Novo Nordisk's newly launched Wegovy pill. Novo called it 'an unapproved, inauthentic, and untested knockoff' and vowed to sue. After the FDA and HHS moved against it, Hims said on February 7 it would stop offering the pill.
HHS Refers Hims to DOJ for Federal Law Violations
HHS General Counsel Mike Stuart referred Hims & Hers to the Department of Justice for potential violations of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 criminal provisions. The referral came one day after the company announced its compounded semaglutide pill, targeting the company's plan to mass-produce copies of Wegovy.
FDA Moves to Restrict Compounded GLP-1 Ingredients, Naming Hims
Responding to Hims' compounded pill launch, the FDA said it would take 'decisive steps' against companies mass-marketing unapproved compounded GLP-1 drugs, including restricting the active pharmaceutical ingredients used to make them, and named Hims & Hers directly. The action threatened the company's weight loss business, whose GLP-1 offering had generated more than $225 million in 2024 revenue.
Second Consecutive Super Bowl Ad Despite Ongoing Controversy
Hims & Hers aired its second consecutive Super Bowl ad, a 60-second spot titled 'Rich People Live Longer' and narrated by Common, positioning the company as an answer to healthcare inequality. Inc. reported the ad cost $16 million. It aired two days after HHS referred Hims to the DOJ and while FDA warning letters, an FTC investigation and securities litigation were outstanding; Novo Nordisk sued the next day.
Novo Nordisk Files Patent Infringement Lawsuit
Novo Nordisk filed a sweeping patent infringement lawsuit against Hims & Hers, targeting the company's 'personalized' compounding formulations of semaglutide and seeking a permanent ban on Hims selling compounded versions of Wegovy and Ozempic. The lawsuit came three days after the FDA's enforcement action and DOJ referral, intensifying the legal pressure from multiple directions simultaneously.
Hims Agrees to Buy Eucalyptus for Up to $1.15 Billion
Hims & Hers agreed to acquire Australian digital health company Eucalyptus, owner of the Juniper weight-loss and Pilot men's health brands, in a deal valued at up to $1.15 billion. The deal added Australia and Japan and deepened its presence in the UK, Germany and Canada. It closed on June 2, 2026.
Hims Discloses SEC Enforcement Investigation
In its annual report, Hims disclosed that the SEC's Division of Enforcement opened an investigation in February 2026 and asked it to preserve documents about its public statements on compounded semaglutide and related business relationships. Shares fell more than 8% after hours.
Novo Drops Patent Suit as Hims Pivots to Branded GLP-1s
Novo Nordisk dropped its patent case after Hims agreed to sell Ozempic and Wegovy at the same price as other telehealth platforms and to stop advertising compounded GLP-1 drugs, keeping compounding for rare clinically necessary cases. Novo reserved the right to refile. Hims shares rose more than 40% in morning trading.
Customer-Support Data Breach Disclosed
Hims notified customers that support tickets on its third-party customer-service platform were accessed without authorization between February 4 and 7, 2026, exposing names, contact details and other data; it said medical records were not affected and offered 12 months of credit monitoring. BleepingComputer reported the ShinyHunters gang used a compromised Okta SSO account to reach Hims' Zendesk instance.
Proxy Shows Dudum Holds 87.7% of Voting Power, 272:1 Pay Ratio
Hims' 2026 proxy statement showed CEO Andrew Dudum held about 87.7% of total voting power through Class V shares carrying 175 votes each, making Hims an NYSE 'controlled company' that may opt out of board-independence rules. Dudum's 2025 compensation was about $23.0 million, 272 times the $84,402 median employee pay.
Net Loss as Hims Shifts to Branded GLP-1s
Hims reported first-quarter 2026 revenue of $608.1 million, up 4%, and a net loss of $92.1 million versus net income of $49.5 million a year earlier, with gross margin falling to 65% from 73% after its pivot toward branded GLP-1 medications. Subscribers reached nearly 2.6 million.
FDA Closes Out MedisourceRx Warning Letter
The FDA told Hims-owned compounding pharmacy MedisourceRx that, based on its evaluation of corrective actions, the firm appeared to have adequately addressed the violations in the December 12, 2025 warning letter.
FTC, Utah and California Sue Hims Over Billing, Cancellation and Health Data
The FTC, joined by Utah and California through Los Angeles County, sued Hims under the FTC Act and ROSCA. The complaint alleges most consumers are charged and enrolled in recurring treatment plans soon after submitting an intake form, without a provider consultation; refill dates are not clearly disclosed; before 2023 most could cancel only via customer service, and later the cancel button was hidden behind 'add/remove items from order'; and Hims shared health information with Meta, Snap and others despite privacy promises.
Hims Rejects FTC Suit After Failed Settlement Talks
Hims denied the FTC's allegations on X, saying the suit 'contorts the law to try to manufacture claims' and vowing to defend itself. CNBC reported the FTC had shared its findings in April, settlement talks followed, and Hims had disclosed a $15 million probable-loss accrual in May. Shares fell sharply on the news.
FOIA Shows Over 4,800 FTC Complaints About Hims
The FTC told Gizmodo it had received over 4,800 complaints about Hims & Hers in five years. The 200 released complaints most often described unwanted subscription charges and refused refunds, alongside trouble reaching customer support and prescriptions issued without real medical advice.
Hims Accrues $60 Million for FTC Case
Hims' second-quarter 10-Q said good-faith settlement negotiations with the FTC failed and that it had recorded a legal contingency accrual of about $60 million for the case as of June 30, 2026, which could change materially. It also reported no share repurchases in the first half of 2026.
New Securities Class Action Follows FTC Suit
An investor filed a securities class action in San Francisco alleging Hims misled shareholders about its privacy and billing practices, after the stock fell almost 15% on the day the FTC suit was announced. The proposed class covers purchases between August 4, 2025 and July 29, 2026.
Evidence (55 citations)
D1: User Value Erosion
D2: Business Customer Exploitation
D3: Shareholder Extraction
D4: Lock-in & Switching Costs
D5: Twiddling & Algorithmic Opacity
D6: Dark Patterns
D7: Advertising & Monetization Pressure
D8: Competitive Conduct
D9: Labor & Governance
D10: Regulatory & Legal Posture
Scoring Log (7 entries)
Checked 88 items + prose. 24 verified, 37 corrected (12 date-only), 22 re-sourced, 5 removed. Invented: Aug 2025 $33M Dudum sale described as under his 10b5-1 plan (Sherwood: open-market sale outside the plan); Dudum pay '97.7% stock' (proxy: $22.7M of $24.6M = 92%); '$49 first month' 2024 GLP-1 pricing (PBS: $49 was the Feb 2026 pill; 2024 injections $199); 'BBB complaints surpassed 300 by mid-2023' (BBB archive May 2023: 203); July 2024 buyback called 'first' (10-K: $50M program Oct 2023); '$3M per week' ad spend (junk-only marketing blogs). Also fixed pill/DOJ dates (2025->2026), MedisourceRx warning letter (Dec 2025) and acquisition (Sept 2024) dates, the expired click-to-cancel rule reference, and stale FTC present tense.
52->49. Since Feb 2026: SEC probe disclosed, Eucalyptus deal ($1.15B, closed Jun 2026), Novo suit dropped and compounded-GLP-1 advertising ended (Mar 9), support-ticket breach, net losses in Q1-Q2, FTC/Utah/California suit (Jul 29) with $60M accrual, new securities suit; MedisourceRx warning letter closed out (the 2026-07-27 FDA letter is a close-out, not a second warning letter as the handoff said). D6 7->8 (event: FTC complaint documents deceptive enrollment at intake and hidden cancellation), D5 4->5 (event: FTC billing-disclosure allegations; medication prices exclude required $149 membership), D10 7->6 (event: compounding retreat and Novo suit dismissal, FDA close-out; still FTC/SEC/DOJ matters), D3 6->4 (recalibration 6->5 for 2025 facts vs criteria plus event: no buybacks and net losses in 2026), D2 3->2 (recalibration: no documented fee extraction from providers/partners), D4 5->4 (recalibration: friction is billing-based, many substitutes). D9 held at 6 but summary corrected (proxy: Dudum 87.7% voting power, 272:1 pay ratio; old text said ~10% owner). Eras: 'SPAC IPO Pressure' and 'Growth-at-All-Costs' merged and re-dated 2021-01-01->2021-01-20 as 'Public-Market Growth Push'; 'GLP-1 Regulatory Gamble' re-dated 2024-06-01->2024-05-20 and split at 2025-02-21 (FDA shortage end) into 'Post-Shortage Compounding'; current era re-dated 2026-02-16->2026-03-09 (Novo deal) and relabeled 'Branded GLP-1 Pivot'; launch era kept. Early eras re-scored from criteria (FTC: support-only cancellation before 2023; dual-class 90% voting since IPO). Trajectory worsening->stable.
Removed typed-in site scores from alternatives text (they go stale on re-score; the page shows live scores). No other changes.
Added 1 missing dimension narrative
Fixed Ro: url changed to slug (ro exists in slug-lookup)